{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T13:33:14Z","timestamp":1792762394666,"version":"4.5.0"},"reference-count":68,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T00:00:00Z","timestamp":1678233600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T00:00:00Z","timestamp":1678233600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Addiction"],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>Long\u2010acting injectable buprenorphine (LAIB) is a new treatment for opioid use disorder that is generating positive outcomes. Negative effects are typically mild and transient, but can occasionally be serious, resulting in treatment discontinuation\/non\u2010adherence. This paper aims to analyse patients\u2019 accounts of how they felt during the first 72\u2009h after initiating LAIB.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Semi\u2010structured interviews were conducted (June 2021\u2013March 2022) with 26 people (18 males and 8 females) who had started LAIB within the previous 72\u2009h. Participants were recruited from treatment services in England and Wales and were interviewed by telephone using a topic guide. Interviews were audio\u2010recorded, transcribed and coded. The concepts of embodiment and embodied cognition framed the analyses. Data on participants\u2019 substance use, initiation onto LAIB and feelings were tabulated. Next, participants\u2019 accounts of how they felt were analysed following the stages of Iterative Categorization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Participants reported complex combinations of changing negative and positive feelings. Bodily experiences included withdrawal symptoms, poor sleep, injection\u2010site pain\/soreness, lethargy and heightened senses inducing nausea (\u2018distressed bodies\u2019), but also enhanced somatic wellbeing, improved sleep, better skin, increased appetite, reduced constipation and heightened senses inducing pleasure (\u2018returning body functions\u2019). Cognitive responses included anxiety, uncertainties and low mood\/depression (\u2018the mind in crisis\u2019) and improved mood, greater positivity and reduced craving (\u2018feeling psychologically better\u2019). Whereas most negative effects reported are widely recognized, the early benefits of treatment described are less well\u2010documented and may be an overlooked distinctive feature of LAIB.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>During the first 72\u2009h after initiating long\u2010acting injectable buprenorphine, new patients report experiencing a range of interconnected positive and negative short\u2010term effects. Providing new patients with information about the range and nature of these effects can prepare them for what to expect and help them manage feelings and reduce anxiety. In turn, this may increase medication adherence.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/add.16171","type":"journal-article","created":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T04:23:31Z","timestamp":1676867011000},"page":"1329-1339","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["How do patients feel during the first 72\u2009h after initiating long\u2010acting injectable buprenorphine? An embodied qualitative analysis"],"prefix":"10.1111","volume":"118","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1502-5983","authenticated-orcid":false,"given":"Joanne","family":"Neale","sequence":"first","affiliation":[{"name":"National Addiction Centre, Institute of Psychiatry, Psychology &amp; Neuroscience King's College London  London SE5 8BB UK"},{"name":"Centre for Social Research in Health University of New South Wales  New South Wales NSW 2052 Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1621-0945","authenticated-orcid":false,"given":"Stephen","family":"Parkin","sequence":"additional","affiliation":[{"name":"National Addiction Centre, Institute of Psychiatry, Psychology &amp; Neuroscience King's College London  London SE5 8BB UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5413-2725","authenticated-orcid":false,"given":"John","family":"Strang","sequence":"additional","affiliation":[{"name":"National Addiction Centre, Institute of Psychiatry, Psychology &amp; Neuroscience King's College London  London SE5 8BB UK"},{"name":"South London and Maudsley (SLaM) NHS Foundation Trust  London SE5 8AZ UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,3,8]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2006.01348.x"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.13539"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-019-0296-4"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/dar.12939"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2020.01.009"},{"key":"e_1_2_10_7_1","unstructured":"Indivior.FDA approves SUBLOCADE\u2122 (buprenorphine extended\u2010release) the first and only once\u2010monthly injectable buprenorphine formulation to treat moderate to severe opioid use disorder. November 30 2017. Available from:https:\/\/www.indivior.com\/en\/media\/press-releases\/fda-approves-sublocade-the-first-and-only-once-monthly-injectable-buprenorphine-forumulation. Accessed August 30th 2022."},{"key":"e_1_2_10_8_1","unstructured":"Camurus.Camurus receives EU approval for weekly and monthly Buvidal\u00ae (CAM2038) for opioid dependence. November 22 2018a. Available from:https:\/\/www.camurus.com\/media\/press-releases\/2018\/camurus-receives-eu-approval-for-weekly-and-monthly-buvidal-cam2038-for-opioid-dependence\/. Accessed August 30th 2022."},{"key":"e_1_2_10_9_1","unstructured":"Camurus.Buvidal\u00ae weekly and Buvidal\u00ae monthly (CAM2038) approved in Australia as the first long\u2010acting treatment of opioid dependence. November 28 2018b. Available from:https:\/\/www.camurus.com\/media\/press-releases\/2018\/buvidal-weekly-and-buvidal-monthly-cam2038-approved-in-australia-as-the-first-long-acting-treatment-of-opioid-dependence\/. Accessed August 30th 2022."},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2019.06.007"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2021.103492"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S180641"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0376-8716(03)00056-5"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S109331"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.31887\/DCNS.2007.9.2\/hkleber"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S72543"},{"key":"e_1_2_10_17_1","volume-title":"Brief clinical guidelines for use of depot buprenorphine (Buvidal\u00ae and Sublocade\u00ae) in the treatment of opioid dependence","author":"Lintzeris N","year":"2019"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.108959"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2017.04.008"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2018.1052"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32259-1"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000647"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.15627"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.9041"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2022.108781"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2022.103788"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13011-022-00474-2"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1037\/pha0000217"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2018.03.057"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.14941"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/jmp\/9.1.29"},{"key":"e_1_2_10_32_1","volume-title":"The absent body","author":"Leder D","year":"1990"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-39405-8_37"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.4135\/9781446222256"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.4135\/9781446215470"},{"key":"e_1_2_10_36_1","volume-title":"Reflexive embodiment in contemporary society","author":"Crossley N","year":"2006"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1177\/0891243205278639"},{"key":"e_1_2_10_38_1","volume-title":"A thousand plateaus: capitalism and schizophrenia","author":"Deleuze G","year":"1987"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.2979\/3270.0"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.4324\/9781315180380"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11097-017-9508-0"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1177\/1357034X02008004001"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1080\/16066350601165448"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0955-3959(01)00095-0"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2004.06.010"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1177\/009145090503200206"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1177\/0038038504039359"},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2017.07.005"},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.4324\/9780429466137"},{"key":"e_1_2_10_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2022.103791"},{"key":"e_1_2_10_51_1","doi-asserted-by":"publisher","DOI":"10.1080\/09687637.2021.1886252"},{"key":"e_1_2_10_52_1","doi-asserted-by":"publisher","DOI":"10.5204\/mcj.1073"},{"key":"e_1_2_10_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2018.02.007"},{"key":"e_1_2_10_54_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091450918781590"},{"key":"e_1_2_10_55_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1467-9566.2010.01278.x"},{"key":"e_1_2_10_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2011.02.040"},{"key":"e_1_2_10_57_1","doi-asserted-by":"publisher","DOI":"10.1177\/1363459312451182"},{"key":"e_1_2_10_58_1","doi-asserted-by":"publisher","DOI":"10.1080\/01459740.2012.694929"},{"key":"e_1_2_10_59_1","doi-asserted-by":"publisher","DOI":"10.1093\/socpro\/spw017"},{"key":"e_1_2_10_60_1","volume-title":"MAXQDA computer programme","author":"VERBI Software","year":"2017"},{"key":"e_1_2_10_61_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.13314"},{"key":"e_1_2_10_62_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.15259"},{"key":"e_1_2_10_63_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.12408"},{"key":"e_1_2_10_64_1","doi-asserted-by":"publisher","DOI":"10.4135\/9781446212295"},{"key":"e_1_2_10_65_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1465-3362.2012.00501.x"},{"key":"e_1_2_10_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-398336-7.00006-1"},{"key":"e_1_2_10_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2021.108667"},{"key":"e_1_2_10_68_1","first-page":"122","article-title":"Narcotic blockade: a medical technique for stopping heroin use by addicts","volume":"79","author":"Dole VP","year":"1966","journal-title":"Trans Assoc Am Physicians"},{"key":"e_1_2_10_69_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091450916666641"}],"container-title":["Addiction"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/add.16171","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/add.16171","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/add.16171","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T17:17:08Z","timestamp":1787591828000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/add.16171"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,8]]},"references-count":68,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["10.1111\/add.16171"],"URL":"https:\/\/doi.org\/10.1111\/add.16171","archive":["Portico"],"relation":{},"ISSN":["0965-2140","1360-0443"],"issn-type":[{"value":"0965-2140","type":"print"},{"value":"1360-0443","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,8]]},"assertion":[{"value":"2022-09-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}